Nanoparticle drug-delivery systems for peritoneal cancers: a case study of the design, characterization and development of the expansile nanoparticle

Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology

Volumn 9, Issue 3, 2017, Pages

  Colby, Aaron H ^a,b   Oberlies, Nicholas H ^c   Pearce, Cedric J ^d   Herrera, Victoria L M ^e   Colson, Yolonda L ^b   Grinstaff, Mark W ^e  

^a BOSTON UNIVERSITY   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c UNIVERSITY OF NORTH CAROLINA AT GREENSBORO   (United States)

^d Mycosynthetix Inc   (United States)

^e BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOTHERAPY; NANOPARTICLES; TUMORS;

ADDITIONAL TREATMENT; DRUG DELIVERY SYSTEM; FLUORESCENT PROBES; INTRAPERITONEAL ROUTE; INTRAVENOUS ADMINISTRATION; LYMPHATIC METASTASIS; PANCREATIC CANCERS; PASSIVE TARGETING;

DISEASES;

EXPANSILE NANOPARTICLE; FLUORESCENT DYE; NANOCARRIER; NANOPARTICLE; PACLITAXEL; UNCLASSIFIED DRUG;

BREAST CANCER; CASE STUDY; CYTOREDUCTIVE SURGERY; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; HUMAN; LYMPH NODE METASTASIS; MESOTHELIOMA; NANOENGINEERING; NANOTECHNOLOGY; NEOPLASM; NONHUMAN; OVARY CANCER; OVERALL SURVIVAL; PANCREAS CANCER; PERITONEAL CAVITY; PERITONEUM; PERITONEUM CANCER; PERITONEUM MESOTHELIOMA; PH; PRIORITY JOURNAL; REVIEW; TUMOR GROWTH; TUMOR XENOGRAFT; CHEMISTRY; FEMALE; OVARIAN NEOPLASMS; PANCREATIC NEOPLASMS; PERITONEAL NEOPLASMS; THERANOSTIC NANOMEDICINE;

DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; NANOPARTICLES; OVARIAN NEOPLASMS; PANCREATIC NEOPLASMS; PERITONEAL NEOPLASMS; THERANOSTIC NANOMEDICINE;

EID: 85013176777     PISSN: 19395116     EISSN: 19390041     Source Type: Journal    
DOI: 10.1002/wnan.1451     Document Type: Review

References (81)

1. Lu Z, Wang J, Wientjes MG, Au JLS. Intraperitoneal therapy for peritoneal cancer. Fut Oncol 2010, 6:1625–1641.
2. Roviello F, Caruso S, Marrelli D, Pedrazzani C, Neri A, De Stefano A, Pinto E. Treatment of peritoneal carcinomatosis with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: state of the art and future developments. Surg Oncol 2011, 20:e38–e54.
3. Imano M, Peng YF, Itoh T, Nishikawa M, Satou T, Yasuda A, Inoue K, Kato H, Shinkai M, Tsubaki M, et al. A preliminary study of single intraperitoneal administration of paclitaxel followed by sequential systemic chemotherapy with S-1 plus paclitaxel for advanced gastric cancer with peritoneal metastasis. Anticancer Res 2012, 32:4071–4075.
4. Innocenti F, Danesi R, Di Paolo A, Agen C, Nardini D, Bocci G, Del Tacca M. Plasma and tissue disposition of paclitaxel (taxol) after intraperitoneal administration in mice. Drug Metab Dispos 1995, 23:713–717.
5. Tristan D, Yan C, Stine Munkholm-Larsen QC. A pharmacological review on intraperitoneal chemotherapy for peritoneal malignancy. World J Gastrointest Oncol 2010, 2:109–116.
6. Tewari D, Java JJ, Salani R, Armstrong DK, Markman M, Herzog T, Monk BJ, Chan JK. Long-term survival advantage and prognostic factors associated with intraperitoneal chemotherapy treatment in advanced ovarian cancer: a gynecologic oncology group study. J Clin Oncol 2015, 33:1460–1466.
7. Tentes A-AK, Kyziridis D, Kakolyris S, Pallas N, Zorbas G, Korakianitis O, Mavroudis C, Courcoutsakis N, Prasopoulos P. Preliminary results of hyperthermic intraperitoneal intraoperative chemotherapy as an adjuvant in resectable pancreatic cancer. Gastroenterol Res Pract 2012, 2012:506571.
8. Vrochides D. NCT02850874 HIPEC as Neoadjuvant Treatment for Resectable Pancreatic Adenocarcinoma, Baishideng Publishing Group Inc.; 2016.
9. Pilot Phase IOpen-label /II Study on Hyperthermic Intraperitoneal Chemotherapy (HIPEC) After Macroscopically Complete Resection (R0/R1) of Adenocarcinomas of the Pancreas (PanHIPEC). Tübingen: University Hospital Tuebingen; 2016.
10. Kazan-Allen L. Asbestos and mesothelioma: worldwide trends. Lung Cancer 2005, 49(suppl 1):S3–S8.
11. Mesothelioma Cancer Trends. Available at: https://www.asbestos.com/mesothelioma/mesothelioma-trends/. (Accessed September 21, 2016)
12. Rowan K. Intraperitoneal therapy for ovarian cancer: why has it not become standard? J Natl Cancer Inst 2009, 101:775–777.
13. Goodman MD, McPartland S, Detelich D, Saif MW. Chemotherapy for intraperitoneal use: a review of hyperthermic intraperitoneal chemotherapy and early post-operative intraperitoneal chemotherapy. J Gastrointest Oncol 2016, 7:45–57.
14. Li J, Tang J, Li Y, Yu J, Zhang B, Yu C. Pharmacokinetic profile of paclitaxel in the plasma, lung, and diaphragm following intravenous or intrapleural administration in rats. Thorac Cancer 2015, 6:43–48.
15. Vasantha J, Kannan G, Goud T, Palani T, Vanitha R, Anitha R, Priya JMM. Pharmacokinetic evaluation of paclitaxel in south Indian cancer patients: a prospective study. J Young Pharm 2011, 3:322–328.
16. Sodek KL, Murphy KJ, Brown TJ, Ringuette MJ. Cell-cell and cell-matrix dynamics in intraperitoneal cancer metastasis. Cancer Metastasis Rev 2012, 31:397–414.
17. Tarin D, Price JE, Kettlewell MG, Souter RG, Vass AC, Crossley B. Mechanisms of human tumor metastasis studied in patients with peritoneovenous shunts. Cancer Res 1984, 44:3584–3592.
18. Coccolini F, Gheza F, Lotti M, Virzì S, Iusco D, Ghermandi C, Melotti R, Baiocchi G, Giulini SM, Ansaloni L, et al. Peritoneal carcinomatosis. World J Gastroenterol 2013, 19:6979–6994.
19. Metintas M, Ak G, Parspour S, Yildirim H, Erginel S, Alatas F, Batirel HF, Sivrikoz C, Metintas S, Dundar E. Local recurrence of tumor at sites of intervention in malignant pleural mesothelioma. Lung Cancer 2008, 61:255–261.
20. Armstrong DK. Relapsed ovarian cancer: challenges and management strategies for a chronic disease. Oncologist 2002, 7:20–28.
21. Kim HJ, Lee WJ, Kang CM, Hwang HK, Bang SM, Song SY, Seong J. Risk factors associated with loco-regional failure after surgical resection in patients with resectable pancreatic cancer. PLoS One 2016, 11:e0157196.
22. De Smet L, Ceelen W, Remon JP, Vervaet C. Optimization of drug delivery systems for intraperitoneal therapy to extend the residence time of the chemotherapeutic agent. Sci World J 2013, 2013:720858.
23. Armstrong DK, Fleming GF, Markman M, Bailey HH. A phase I trial of intraperitoneal sustained-release paclitaxel microspheres (Paclimer) in recurrent ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol 2006, 103:391–396.
24. Delgado G, Potkul RK, Treat JA, Lewandowski GS, Barter JF, Forst D, Rahman A. A phase I/II study of intraperitoneally administered doxorubicin entrapped in cardiolipin liposomes in patients with ovarian cancer. Am J Obstet Gynecol 1989, 160:812–817; discussion 817–819.
25. Sugiyama T, Kumagai S, Nishida T, Ushijima K, Matsuo T, Yakushiji M, Hyon SH, Ikada Y. Experimental and clinical evaluation of cisplatin-containing microspheres as intraperitoneal chemotherapy for ovarian cancer. Anticancer Res 1998, 18:2837–2842.
26. Verschraegen CF, Kumagai S, Davidson R, Feig B, Mansfield P, Lee SJ, Maclean DS, Hu W, Khokhar AR, Siddik ZH. Phase I clinical and pharmacological study of intraperitoneal cis-bis-neodecanoato(trans-R, R-1, 2-diaminocyclohexane)-platinum II entrapped in multilamellar liposome vesicles. J Cancer Res Clin Oncol 2003, 129:549–555.
27. Petros RA, DeSimone JM. Strategies in the design of nanoparticles for therapeutic applications. Nat Rev Drug Discov 2010, 9:615–627.
28. Davis ME, Chen Z, Shin DM. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov 2008, 7:771–782.
29. Hofmann-Amtenbrink M, Grainger DW, Hofmann H. Nanoparticles in medicine: current challenges facing inorganic nanoparticle toxicity assessments and standardizations. Nanomed Nanotechnol Biol Med 2015, 11:1689–1694.
30. Oberoi HS, Nukolova NV, Kabanov AV, Bronich TK. Nanocarriers for delivery of platinum anticancer drugs. Adv Drug Deliv Rev 2013, 65:1667–1685.
31. Svenson S. What nanomedicine in the clinic right now really forms nanoparticles? Wiley Interdiscip Rev Nanomed Nanobiotechnol 2014, 6:125–135.
32. He C, Liu D, Lin W. Nanomedicine applications of hybrid nanomaterials built from metal–ligand coordination bonds: nanoscale metal–organic frameworks and nanoscale coordination polymers. Chem Rev 2015, 115:11079–11108.
33. Griset AP, Walpole J, Liu R, Gaffey A, Colson YL, Grinstaff MW. Expansile nanoparticles: synthesis, characterization, and in vivo efficacy of an acid-responsive polymeric drug delivery system. J Am Chem Soc 2009, 131:2469–2471.
34. Colby AH, Colson YL, Grinstaff MW. Microscopy and tunable resistive pulse sensing characterization of the swelling of pH-responsive, polymeric expansile nanoparticles. Nanoscale 2013, 5:3496–3504.
35. Li X-F, O'Donoghue JA. Hypoxia in microscopic tumors. Cancer Lett 2008, 264:172–180.
36. Brown JM. Tumor hypoxia in cancer therapy. Methods Enzymol 2007, 435:297–321.
37. Zubris KAV, Colson YL, Grinstaff MW. Hydrogels as intracellular depots for drug delivery. Mol Pharm 2012, 9:196–200.
38. Herrera VL, Colby AH, Tan GA, Moran AM, O'Brien MJ, Colson YL, Ruiz-Opazo N, Grinstaff MW. Evaluation of expansile nanoparticle tumor localization and efficacy in a cancer stem cell-derived model of pancreatic peritoneal carcinomatosis. Nanomedicine 2016, 11:1001–1015.
39. Colson YL, Liu R, Southard EB, Schulz MD, Wade JE, Griset AP, Zubris KA, Padera RF, Grinstaff MW. The performance of expansile nanoparticles in a murine model of peritoneal carcinomatosis. Biomaterials 2011, 32:832–840.
40. Weatherall E, Thomos L, Dickinson M, Colby AH, Grinstaff MW, Willmott GR. Tunable resistive pulse sensing and nanoindentation of pH-responsive expansile nanoparticles. Int J Nanotechnol 2016, 14:1–11.
41. Au JL-S, Li D, Gan Y, Gao X, Johnson AL, Johnston J, Millenbaugh NJ, Jang SH, Kuh H-J, Chen C-T, et al. Pharmacodynamics of immediate and delayed effects of paclitaxel: role of slow apoptosis and intracellular drug retention. Cancer Res 1998, 58:2141–2148.
42. Zubris KA, Liu R, Colby A, Schulz MD, Colson YL, Grinstaff MW. In vitro activity of paclitaxel-loaded polymeric expansile nanoparticles in breast cancer cells. Biomacromolecules 2013, 14:2074–2082.
43. Liu R, Colby AH, Gilmore D, Schulz M, Zeng J, Padera RF, Shirihai O, Grinstaff MW, Colson YL. Nanoparticle tumor localization, disruption of autophagosomal trafficking, and prolonged drug delivery improve survival in peritoneal mesothelioma. Biomaterials 2016, 102:175–186.
44. Lei H, Hofferberth SC, Liu R, Colby A, Tevis KM, Catalano P, Grinstaff MW, Colson YL. Paclitaxel-loaded expansile nanoparticles enhance chemotherapeutic drug delivery in mesothelioma 3-dimensional multicellular spheroids. J Thorac Cardiovasc Surg 2015, 149:1417–1425.
45. Colby AH, Berry S, Paison K, Liu R, Colson YL, Ruiz-Opazo N, Grinstaff MW, Herrera V. Highly specific and sensitive fluorescent nanoprobes for image-guided resection of sub-millimeter peritoneal tumors. ACS Nano, 2017, In press.
46. Mosesson Y, Mills GB, Yarden Y. Derailed endocytosis: an emerging feature of cancer. Nat Rev Cancer 2008, 8:835–850.
47. Vassileva V, Allen CJ, Piquette-Miller M. Effects of sustained and intermittent paclitaxel therapy on tumor repopulation in ovarian cancer. Mol Cancer Ther 2008, 7:630–637.
48. Demidenko ZN, Kalurupalle S, Hanko C, Lim CU, Broude E, Blagosklonny MV. Mechanism of G1-like arrest by low concentrations of paclitaxel: next cell cycle p53-dependent arrest with sub G1 DNA content mediated by prolonged mitosis. Oncogene 2008, 27:4402–4410.
49. Lu Z, Tsai M, Lu D, Wang J, Wientjes MG, Au JL. Tumor-penetrating microparticles for intraperitoneal therapy of ovarian cancer. J Pharmacol Exp Ther 2008, 327:673–682.
50. Wright AA, Cronin A, Milne DE, Bookman MA, Burger RA, Cohn DE, Cristea MC, Griggs JJ, Keating NL, Levenback CF, et al. Use and effectiveness of intraperitoneal chemotherapy for treatment of ovarian cancer. J Clin Oncol 2015, 33:2841–2847.
51. Wenzel LB, Huang HQ, Armstrong DK, Walker JL, Cella D, Group GO. Health-related quality of life during and after intraperitoneal versus intravenous chemotherapy for optimally debulked ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2007, 25:437–443.
52. Walker JL, Armstrong DK, Huang HQ, Fowler J, Webster K, Burger RA, Clarke-Pearson D. Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study. Gynecol Oncol 2006, 100:27–32.
53. Verwaal VJ, van Tinterin H, Ruth SV, Zoetmulder FAN. Toxicity of cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy. J Surg Oncol 2004, 85:61–67.
54. Verwaal VJ, Kusamura S, Baratti D, Deraco M. The eligibility for local-regional treatment of peritoneal surface malignancy. J Surg Oncol 2008, 98:220–223.
55. Gilmore MD, Schulz MM, Liu MR, PhD, Zubris PKAV, Padera MRF, Catalano SPJ, Grinstaff PMW, Colson MYL. Cytoreductive surgery and intraoperative administration of paclitaxel-loaded expansile nanoparticles delay tumor recurrence in ovarian carcinoma. Ann Surg Oncol 2013, 20:1684–1693.
56. Glavinas H, Krajcsi P, Cserepes J, Sarkadi B. The role of ABC transporters in drug resistance, metabolism and toxicity. Curr Drug Deliv 2004, 1:27–42.
57. Beck B, Blanpain C. Unravelling cancer stem cell potential. Nat Rev Cancer 2013, 13:727–738.
58. Nguyen LV, Vanner R, Dirks P, Eaves CJ. Cancer stem cells: an evolving concept. Nat Rev Cancer 2012, 12:133–143.
59. Chand S, O'Hayer K, Blanco FF, Winter JM, Brody JR. The landscape of pancreatic cancer therapeutic resistance mechanisms. Int J Biol Sci 2016, 12:273–282.
60. Charoen KM, Fallica B, Colson YL, Zaman MH, Grinstaff MW. Embedded multicellular spheroids as a biomimetic 3D cancer model for evaluating drug and drug-device combinations. Biomaterials 2014, 35:2264–2271.
61. Fisher B, Jeong JH, Anderson S, Bryant J, Fisher ER, Wolmark N. Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation. N Engl J Med 2002, 347:567–575.
62. Liu R, Gilmore DM, Zubris KA, Xu X, Catalano PJ, Padera RF, Grinstaff MW, Colson YL. Prevention of nodal metastases in breast cancer following the lymphatic migration of paclitaxel-loaded expansile nanoparticles. Biomaterials 2013, 34:1810–1819.
63. Green DJ, Pagel JM, Nemecek ER, Lin Y, Kenoyer A, Pantelias A, Hamlin DK, Wilbur DS, Fisher DR, Rajendran JG, et al. Pretargeting CD45 enhances the selective delivery of radiation to hematolymphoid tissues in nonhuman primates. Blood 2009, 114:1226–1235.
64. Park SI, Shenoi J, Frayo SM, Hamlin DK, Lin Y, Wilbur DS, Stayton PS, Orgun N, Hylarides M, Buchegger F, et al. Pretargeted radioimmunotherapy using genetically engineered antibody-streptavidin fusion proteins for treatment of non-hodgkin lymphoma. Clin Cancer Res 2011, 17:7373–7382.
65. Colby AH, Liu R, Schulz MD, Padera RF, Colson YL, Grinstaff MW. Two-step delivery: exploiting the partition coefficient concept to increase intratumoral paclitaxel concentrations in vivo using responsive nanoparticles. Sci Rep 2016, 6:18720.
66. von Maltzahn G, Park J-H, Lin KY, Singh N, Schwöppe C, Mesters R, Berdel WE, Ruoslahti E, Sailor MJ, Bhatia SN. Nanoparticles that communicate in vivo to amplify tumour targeting. Nat Mater 2011, 10:545–552.
67. Park JH, von Maltzahn G, Xu MJ, Fogal V, Kotamraju VR, Ruoslahti E, Bhatia SN, Sailor MJ. Cooperative nanomaterial system to sensitize, target, and treat tumors. Proc Natl Acad Sci U S A 2010, 107:981–986.
68. Simberg D, Duza T, Park JH, Essler M, Pilch J, Zhang L, Derfus AM, Yang M, Hoffman RM, Bhatia S, et al. Biomimetic amplification of nanoparticle homing to tumors. Proc Natl Acad Sci U S A 2007, 104:932–936.
69. Meng H, Zhao Y, Dong J, Xue M, Lin Y-S, Ji Z, Mai WX, Zhang H, Chang CH, Brinker CJ, et al. Two-wave nanotherapy to target the stroma and optimize gemcitabine delivery to a human pancreatic cancer model in mice. ACS Nano 2013, 7:10048–10065.
70. Brudno Y, Silva EA, Kearney CJ, Lewin SA, Miller A, Martinick KD, Aizenberg M, Mooney DJ. Refilling drug delivery depots through the blood. Proc Natl Acad Sci U S A 2014, 111:12722–12727.
71. Oberlies NH, Kroll DJ. Camptothecin and taxol: historic achievements in natural products research. J Nat Prod 2004, 67:129–135.
72. Camidge R. The story of taxol: nature and politics in the pursuit of an anti-cancer drug. Br Med J 2001, 323:115.
73. Oroudjev E, Lopus M, Wilson L, Audette C, Provenzano C, Erickson H, Kovtun Y, Chari R, Jordan MA. Maytansinoid-antibody conjugates induce mitotic arrest by suppressing microtubule dynamic instability. Mol Cancer Ther 2010, 9:2700–2713.
74. Liu F, Liu Q, Yang D, Bollag WB, Robertson K, Wu P, Liu K. Verticillin A overcomes apoptosis resistance in human colon carcinoma through DNA methylation-dependent upregulation of BNIP3. Cancer Res 2011, 71:6807–6816.
75. Paschall AV, Yang D, Lu C, Choi JH, Li X, Liu F, Figueroa M, Oberlies NH, Pearce C, Bollag WB, et al. H3K9 trimethylation silences Fas expression to confer colon carcinoma immune escape and 5-fluorouracil chemoresistance. J Immunol 2015, 195:1868–1882.
76. Grinstaff MW, Soon-Shiong P, Wong M, Sandford PA, Suslick KS, Desai NP. Composition useful for in vivo delivery of biologics and methods employing same. US5498421; 1996.
77. Grinstaff MW, Soon-Shiong P, Wong M, Sandford PA, Suslick KS, Desai NP. Methods for the preparation of pharmaceutically active agents for in vivo delivery. US5665382; 1997.
78. Desai NP, Soon-Shiong P, Sandford PA, Grinstaff MW, Suslick KS. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor. US5439686; 1995.
79. Soon-Shiong P, Desai NP, Grinstaff MW, Sandford PA, Suslick KS. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor. US5439686; 1995.
80. Protein-bound paclitaxel. Wikimedia Foundation, Inc. Available from https://en.wikipedia.org/wiki/Protein-bound_paclitaxel.
81. FDA. FDA Approves New Drug for the Most Common Type of Lung Cancer Drug Shows Survival Benefit; 2004.